Table 4. Antiproliferative Activity of Selected Compounds against a Diverse Panel of ALK-Positive Cell Lines.
| IC50 (μM)a |
||||||
|---|---|---|---|---|---|---|
| cell line | histology | 15a | 20a | 23a | 1 | 2 |
| Tel-ALK-Ba/F3 | 0.07 | 0.04 | 0.02 | 0.001 | 0.19 | |
| EML4-ALK-Ba/F3 | NSCLC | 0.14 | 0.26 | 0.03 | 0.02 | 0.28 |
| EML4-ALK (F1174L)-Ba/F3 | NSCLC | 0.72 | 2.1 | 0.29 | 0.06 | 0.62 |
| EML4-ALK (L1196M)-Ba/F3 | NSCLC | 0.62 | 2.3 | 0.11 | 0.08 | 2.2 |
| Kelly (F1174L) | neuroblastoma | 0.18 | 0.25 | 0.07 | 0.38 | 0.42 |
| SH-SY5Y (F1174L) | neuroblastoma | 0.68 | 2.0 | 0.23 | 0.16 | 0.53 |
| SMS-KCN (R1275Q) | neuroblastoma | 3.8 | 4.0 | 1.3 | 0.52 | 0.91 |
| SU-DHL-1 (NPM-ALK) | ALCL | 0.01 | 0.08 | 0.001 | NDb | 0.01 |
a
The data are expressed as the required compound concentration for inhibiting cell growth at 50%; values are means of two experiments, and the standard deviation is less than 10% of means.
b
Not determined.